Amgen Joins China Oncology Market Race With $2.7bn BeiGene Stake
Executive Summary
As China embraces novel new drugs, oncology is quickly becoming the biggest opportunity for pharma to drive growth in this market. Amgen is the latest to jump on board through the purchase of a significant stake in BeiGene.
You may also be interested in...
Biopharma Quarterly Dealmaking Statistics, Q4 2019
Financing for biopharma companies increased by 19% in Q4 to $15.8bn. M&A value quadrupled, compared with Q3, thanks to nine billion-dollar-plus transactions, led by the buy-out of Nestle Skin Health, now Galderma.Among the key alliances of Q4 were recurring themes of gene therapy and oncology, but also big investments in oligonucleotide technologies.
Amgen’s R&D Group Focuses On Efficiency As Drug Cost Concerns Continue
Scrip spoke with R&D head David Reese about improving R&D timelines and success rates, including through the use of genomics and proteomics, as data readouts near for key drugs in big indications.
J.P. Morgan Day 3: Skyrizi Momentum Builds, What's Next For Amarin, Viatris Debuts And More
Daily round-up from the J.P. Morgan Healthcare Conference in San Francisco: AbbVie's Skyrizi takes psoriasis lead, Amarin goes it alone, Viatris debuts, BeiGene on US drug pricing and Roche think neuroscience is the new oncology.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
